CA2812699A1 - Inhibiteurs du virus de l'hepatite c - Google Patents

Inhibiteurs du virus de l'hepatite c Download PDF

Info

Publication number
CA2812699A1
CA2812699A1 CA2812699A CA2812699A CA2812699A1 CA 2812699 A1 CA2812699 A1 CA 2812699A1 CA 2812699 A CA2812699 A CA 2812699A CA 2812699 A CA2812699 A CA 2812699A CA 2812699 A1 CA2812699 A1 CA 2812699A1
Authority
CA
Canada
Prior art keywords
mmol
anal
calcd
found
cond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2812699A
Other languages
English (en)
Inventor
Makonen Belema
Piyasena Hewawasam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2812699A1 publication Critical patent/CA2812699A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA2812699A 2010-09-24 2010-09-24 Inhibiteurs du virus de l'hepatite c Abandoned CA2812699A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/050138 WO2012039717A1 (fr) 2010-09-24 2010-09-24 Inhibiteurs du virus de l'hépatite c

Publications (1)

Publication Number Publication Date
CA2812699A1 true CA2812699A1 (fr) 2012-03-29

Family

ID=43037168

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2812699A Abandoned CA2812699A1 (fr) 2010-09-24 2010-09-24 Inhibiteurs du virus de l'hepatite c

Country Status (8)

Country Link
EP (1) EP2619195A1 (fr)
JP (1) JP5619289B2 (fr)
CN (1) CN103249730A (fr)
BR (1) BR112013008148A2 (fr)
CA (1) CA2812699A1 (fr)
EA (1) EA201370078A1 (fr)
MX (1) MX2013002927A (fr)
WO (1) WO2012039717A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737601C (fr) 2009-06-11 2014-10-21 Abbott Laboratories Composes antiviraux
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
IN2012DN00999A (fr) 2009-07-16 2015-04-10 Vertex Pharma
CA2794145A1 (fr) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues pour traiter ou prevenir les infections a flavivirus
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
BR112013004520A2 (pt) 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013030750A1 (fr) 2011-09-01 2013-03-07 Lupin Limited Composés antiviraux
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
IN2014MN01547A (fr) 2012-02-10 2015-05-08 Lupin Ltd
KR101995683B1 (ko) 2012-06-04 2019-07-02 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체
CA2885180C (fr) 2012-10-10 2021-03-02 Actelion Pharmaceuticals Ltd Antagonistes des recepteurs de l'orexine, qui sont des derives [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
KR102615161B1 (ko) 2017-03-31 2023-12-15 신젠타 파티서페이션즈 아게 살진균 조성물
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
WO2024259085A2 (fr) * 2023-06-14 2024-12-19 Alexion Pharmaceuticals, Inc. Procédés de synthèse d'inhibiteurs du facteur d du complément et intermédiaires de ceux-ci

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7183302B2 (en) 2002-08-12 2007-02-27 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of HCV replication
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE102004036971B4 (de) 2004-07-30 2009-07-30 Advanced Micro Devices, Inc., Sunnyvale Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010034721A (ja) * 2008-07-28 2010-02-12 Fujitsu Ltd パケットキャプチャ装置,パケットキャプチャ方法およびパケットキャプチャプログラム
JP2012510523A (ja) * 2008-12-03 2012-05-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Hcvns5aの阻害剤
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
CN103249730A (zh) 2013-08-14
JP5619289B2 (ja) 2014-11-05
WO2012039717A1 (fr) 2012-03-29
MX2013002927A (es) 2013-05-30
BR112013008148A2 (pt) 2016-08-09
EP2619195A1 (fr) 2013-07-31
EA201370078A1 (ru) 2013-11-29
JP2013537905A (ja) 2013-10-07

Similar Documents

Publication Publication Date Title
EP2414350B1 (fr) Inhibiteurs de la virus hepatitis c
CA2758047C (fr) Inhibiteurs du virus de l'hepatite c
US9776981B2 (en) Hepatitis C virus inhibitors
CA2780790C (fr) Inhibiteurs du virus de l'hepatite c
EP2146984B1 (fr) Inhibiteurs du virus de l'hépatite c
AU2010332034B2 (en) Hepatitis C virus inhibitors
EP2435429B1 (fr) Inhibiteurs du virus de l'hépatite c
EP2398794B1 (fr) Inhibiteurs du virus de l'hépatite c
CA2812699A1 (fr) Inhibiteurs du virus de l'hepatite c
US20110237636A1 (en) Hepatitis C Virus Inhibitors
WO2011060000A1 (fr) Inhibiteurs du virus de l'hépatite c
AU2009214997A1 (en) Hepatitis C virus inhibitors
AU2010358561A1 (en) Hepatitis C virus inhibitors
AU2010319764B2 (en) Hepatitis C virus inhibitors
HK1163067B (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150918

FZDE Discontinued

Effective date: 20170926